Gerinnungsspezifische Therapie der aneurysmatischen Subarachnoidalblutung

A Thie

doi:10.1055/s-0038-1655180

Hämostaseologie, Table of Contents

Hamostaseologie 1990; 10(01): 45-51
DOI: 10.1055/s-0038-1655180

Originalarbeiten

Schattauer GmbH

Gerinnungsspezifische Therapie der aneurysmatischen Subarachnoidalblutung

A Thie

¹Neurologische Universitätsklinik Hamburg-Eppendorf (Direktor: Univ.-Prof. Dr. K. Kunze)

› Author Affiliations

Abstract

Full Text

References

LITERATUR
1 Adams Jr HP. Early management of the patient with recent aneurysmal subarachnoid hemorrhage. Stroke 1986; 17: 1068-70.
2 Adams Jr HP, Jergenson DD, Kassell NF, Sahs AL. Pitfalls in the recognition of subarachnoid hemorrhage. J Am Med Assoc 1980; 244: 794-6.
3 Adams Jr HP, Kassell NF, Torner JC, Haley Jr EC. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology 1987; 37: 1586-91.
4 Adams Jr HP, Kassell NF, Torner JC, Sahs AL. CT and clinical correlations in recent aneurysmal subarachnoid hemorrhage: a preliminary report of the Cooperative Aneurysm Study. Neurology 1983; 33: 981-8.
5 Adams Jr HP, Nibbelink DW, Torner JC. et al. Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative study. Arch Neurol 1981; 38: 25-9.
6 Ameen AA, Illingworth R. Anti-fibrinolytic treatment in the preoperative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm. J Neurol Neurosurg Psychiatry 1981; 44: 220-6.
7 Amris CJ. Inhibition of fibrinolytic and thromboplastic activity by Trasylol. Scand J Haematol 1966; 03: 19-32.
8 Beck DW, Adams HP, Flamm ES. et al. Combination of aminocaproic acid and nicardipine in treatment of aneurysmal subarachnoid hemorrhage. Stroke 1988; 19: 63-7.
9 Burchiel KJ, Hoffman JM, Bakay RAE. Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving Eaminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition. Neurosurgery 1984; 14: 57-63.
10 Burchiel KJ, Schmer G. A method for monitoring antifibrinolytic therapy in patients with ruptured intracranial aneurysms. J Neurosurg 1981; 54: 12-5.
11 Cameron N. Abstr Proc Soc Br Neurol Surg J Neurol Neurosurg Psychiatry. 1979; 42: 963.
12 Chandra B. Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Ann Neurol 1978; 03: 502-4.
13 Chimowitz MI, Pessin MS. Is there a role for heparin in the management of complications of subarachnoid hemorrhage?. Stroke 1987; 18: 1169-72.
14 Chowdhary HM, Carey PC, Hussein MM. Prevention of early recurrence of spontaneous subarachnoid haemorrhage by E-aminocaproic acid. Lancet 1979; I: 741-3.
15 Corkill G. Earlier operation and antifibrinolytic therapy in the management of aneurysmal subarachnoid hemorrhage. Med J Aust 1974; 01: 468-70.
16 De Vivo D, Kline E, Dodge PR. Influence of human cerebrospinal fluid on blood coagulation in vitro. Arch Neurol 1965; 13: 615-20.
17 Ettinger MG. Coagulation abnormalities in subarachnoid hemorrhage. Stroke 1970; 01: 139-42.
18 Ewald T, Mahaley S, Goodrich J. et al. Experimental epsilon-aminocaproic acid (EACA) administration in the presence of subarachnoid blood. J Neurosurg 1971; 35: 657-63.
19 Filizzolo F, D’Angelo V, Collice M. Fibrinolytic activity in blood and cerebrospinal fluid in subarachnoid hemorrhage from ruptured intracranial saccular aneurysms before and during EACA treatment. Eur Neurol 1978; 17: 43-7.
20 Findlay JM, Weir BKA, Steinke D. et al. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH. J Neurosurg 1988; 69: 723-35.
21 Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980; 06: 1-9.
22 Fodstad G, Forssell A, Liliequist B, Schannong M. Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery 1981; 08: 158-65.
23 Fodstad H, Liliequist B, Schannong M, Thulin C. Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surg Neurol 1978; 10: 9-15.
24 Fodstad H, Nilsson IM. Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid. Acta Neurochir (Wien) 1981; 56: 25-38.
25 Fodstad H, Pilbrant A, Schannong M. et al. Determination of tranexamic acid and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 1981; 58: 1-13.
26 Gelmers HJ. Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid. Acta Neurochir (Wien) 1980; 52: 45-50.
27 Geronemus R, Hertz DA, Shulman K. Streptokinase clot lysis time in patients with ruptured intracranial aneurysms. J Neurosurg 1974; 40: 499-503.
28 Gibbs JR, Corkill AGL. Use of an antifibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms. Postgrad Med J 1971; 47: 199-200.
29 Gibbs JR, O’Gorman O. Fibrinolysis in subarachnoid haemorrhage. Postgrad Med J 1967; 43: 779-84.
30 Girvin GP. The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Trans Am Neurol Assoc Proceedings of 98th meeting 1973; 150.
31 Glick R, Green R, Ts’Ao C. et al. High dose E-aminocaproic acid prolongs the bleeding time and increases rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage. Neurosurgery 1981; 09: 398-401.
32 Green R, Ts’Ao C, Cerullo L. et al. Clinical and laboratory investigation of the effects of E-aminocaproic acid on hemostasis. J Lab Clin Med 1985; 105: 321-7.
33 Guidetti B, Spallone A. The role of antifibrinolytic therapy in the pre-operative management of recently ruptured intracranial aneurysms. Surg Neurol 1981; 15: 239-48.
34 Hasan D, Vermeulen M, Wijdicks EJM. et al. Management problems in acute hydrocephalus after subarachnoid hemorrhage. Stroke 1989; 20: 747-53.
35 Hashimoto N, Kikushi H, Kang Y. et al. Effects of exogenous factor XIII on experimentally induced cerebral aneurysms in rats. Stroke 1989; 20: 141.
36 Hasler O, Fodstad H. Fibrinolytic activity in the walls of cerebral saccular aneurysms. Acta Neurochir (Wien) 1977; 37: 49-55.
37 Henriksson P, McDonagh J. Factor XIII activation and interactions. In: Factor XIII and Fibronectin. Egbring R, Klingemann H-G. (eds). Marburg: Medizinische Verlagsgesellschaft; 1983: 1-14.
38 Heros RC, Zervas NT, Varsos V. Cerebral vasospasm after subarachnoid hemorrhage: an update. Ann Neurol 1983; 04: 599-608.
39 Hindersin P, Heidrich R, Endler S. Haemostasis in cerebrospinal fluid. Acta Neurochir (Wien) 1984; 34 (Suppl): 1-77.
40 Imanaga H, Osugi T, Kagawa M. et al. Fibrinolytic activity in cerebrospinal fluid in subarachnoid hemorrhage. Neurol Surg (Tokyo) 1977; 05: 51-8.
41 Ishii M, Suzuki S, Iwabuchi T, Julow J. Effect of antifibrinolytic therapy on subarachnoid fibrosis in dogs after experimental subarachnoid haemorrhage. Acta Neurochir (Wien) 1980; 54: 17-24.
42 Janzen RWC, Bauer W, Tilsner V. The spontaneous course of factor XIII following intracranial hemorrhage: relevant for rebleeding?. J Neurosurg Sci 1982; 26: 135-6.
43 Kapp JP, Neill WR, Neill CL. et al. The three phases of vasospasm. Surg Neurol 1982; 18: 40-5.
44 Kassell NF, Torner JC. Aneurysmal rebleeding: a preliminary report from the Cooperative Aneurysm Study. Neurosurgery 1983; 13: 479-81.
45 Kassell NF, Tomer JC, Adams Jr HP. Antifibrinolytic therapy in the acute period following aneurysmal subarachnoid haemorrhage. J Neurosurg 1984; 61: 225-30.
46 Kaste M, Ramsay M. Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke 1979; 10: 519-21.
47 Kistler JP, Crowell RM, Davis KR. et al. The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT scan: a prospective study. Neurology 1983; 33: 424-36.
48 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45.
49 Lindsay KW. Antifibrinolytic agents in subarachnoid haemorrhage. J Neurol 1987; 234: 1-8.
50 Maurice-Williams RS. Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms. Br Med J 1978; 01: 945-7.
51 Maurice-Williams RS, Gordon YB, Sykes A. Monitoring fibrinolytic activity in the cerebrospinal fluid after subarachnoid haemorrhage: a guide to the risk of rebleeding?. J Neurol Neurosurg Psychiatry 1980; 43: 175-81.
52 McNicol GP, Fletcher AP, Alkjaersi GN, Sherry S. The absorption, distribution and excretion of E-aminocaproic acid following oral or intravenous administration to man. J Lab Clin Med 1962; 59: 15-24.
53 Mihara H, Fuji T, Okamoto S. Fibrinolytic activity of cerebrospinal fluid and the development of artificial cerebral hemorrhage. Thromb Diath Haemorrh 1969; 21: 294-303.
54 Moltke P. Investigations sur la teneur du systeme nerveux centrale en activateur de plasminogene. Trans 6th Congress Eur Soc Haematol 1957; 02: 475-77.
55 Moltke P. Plasminogen activator in animal meninges. Proc Soc Exp Biol Med 1958; 98: 377-9.
56 Mullan S, Dawley J. Antifibrinolytic therapy for intracranial aneurysms. J Neurosurg 1968; 28: 21-3.
57 Mullan S, Hanlon H, Brown F. Management of 136 consecutive supratentorial berry aneurysms. J Neurosurg 1978; 49: 794-804.
58 Nibbelink DW, Torner JC, Henderson WC. Intracranial aneurysms and subarachnoid hemorrhage : a cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke 1975; 06: 622-9.
59 Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acid. J Clin Pathol. 1980 33. (Suppl 14): 41-7.
60 Nilsson IM, Sjoerdsma A, Waidestrom J. Antifibrinolytic activity and metabolism of epsilon aminocaproic acid in man. Lancet 1960; I: 1322-4.
61 Norlen G, Thulin CA. The use of antifibrinolytic substances in intracranial aneurysms. Neurochirurgia 1969; 12: 100-2.
62 Okamoto S, Okamoto V. Amino-methylcyclohexane-carboxylic acid: AMCHA: a new potent inhibitor of fibrinolysis. Keio J Med 1962; 11: 105-15.
63 Pakarinen S. Incidence, aetiology and prognosis of primary subarachnoid haemorrhage. Acta Neurol Scand 1967; 48 (Suppl 29): 1-128.
64 Patterson RH, Harpel P. The effect of epsilon-aminocaproic acid and tranexamic acid on thrombus size and strength in a simulated arterial aneurysm. J Neurosurg 1971; 34: 365-71.
65 Petruk KC, West M, Mohr G. et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter doubleblind placebo-controlled trial. J Neurosurg 1988; 68: 505-17.
66 Pickard JD, Murray GD, Illingworth R. et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage. British aneurysm nimodipine trial. Br Med J 1989; 298: 636-42.
67 Porter JM, Acinapura AJ, Kapp JP. et al. Fibrinolytic activity of the spinal fluid and meninges. Surg Forum 1966; 17: 425-7.
68 Porter JM, Acinapura AJ, Kapp JP. et al. Fibrinolysis in the central nervous system. Neurology 1969; 19: 47-52.
69 Post KD, Flamm ES, Goodgold A, Ransohoff J. Ruptured intracranial aneurysms, case morbidity and mortality. J Neurosurg 1977; 46: 290-95.
70 Prentice CRM. Basis of antifibrinolytic therapy. J Clin Pathol 1980; 33 (Suppl 14): 35-40.
71 Profeta G, Castellano F, Guarnieri L. et al. Antifibrinolytic therapy in the treatment of subarachnoid hemorrhage caused by arterial aneurysms. J Neurol Sci 1975; 19: 77-8.
72 Ramirez-Lassepas M. Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm. Neurology 1981; 31: 316-22.
73 Ransohoff J, Goodgold A, Benjamin MV. Preoperative management of patients with ruptured intracranial aneurysms. J Neurosurg 1972; 36: 525-30.
74 Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology. A basic science for clinical medicine. Boston: Little, Brown; 1985
75 Sakata Y, Aoki N. Cross-linking of alpha2plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
76 Sawaya R, Sonnino V, McLaurin RL, Perrotta G. Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of CSF fibrin/fibrinogen degradation products. J Neurosurg 1983; 58: 699-707.
77 Schisano G. The use of antifibrinolytic drugs in aneurysmal subarachnoid haemorrhage. Surg Neurol 1978; 10: 217-22.
78 Sengupta RP, So SC, Villarejo-Ortega FJ. Use of epsilon aminocaproic acid (EACA) in the pre-operative management of ruptured intracranial aneurysms. J Neurosurg 1976; 44: 479-84.
79 Shaw MDM, Miller JD. Epsilon aminocaproic acid and subarachnoid haemorrhage. Lancet 1974; I: 847-8.
80 Shucart WA, Hussain SK, Cooper PR. Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage. J Neurosurg 1980; 53: 28-31.
81 Solomon RA, Fink ME. Current strategies for the management of aneurysmal subarachnoid hemorrhage. Arch Neurol 1987; 44: 769-74.
82 Spallone A, Pastore FS, Rizzo A, Guidetti B. Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. Neurochirurgia (Stuttg) 1987; 30: 172-6.
83 Steinmetz H, Grote E. The fibrinolytic activity of cerebrospinal fluid after subarachnoid hemorrhage. Neurol Res 1983; 05: 59-65.
84 Takashima S, Koga M, Tanaka K. Fibrinolytic activity of human brain and cerebrospinal fluid. Br J Exp Pathol 1969; 50: 533-9.
85 Thie A. Zur Therapie aneurysmatischer Subarachnoidalblutungen. Die gelben Hefte 1987; 27: 158-65.
86 Thie A, Henze T, Degener D. et al. Factor XIII concentrate for prophylaxis of rebleeding in subarachnoid hemorrhage (SAH) results of a prospective multicenter pilot study. Thromb Haemost 1987; 58: 142.
87 Thie A, Henze T. for the FIS AH Study Group. Factor XIII concentrate for prevention of recurrent subarachnoid hemorrhage : results of a multicenter pilot study. (im Druck)
88 Thie A, Spitzer K, Kunze K. Spontaneous subarachnoid hemorrhage: assessment of prognosis and initial management in the intensive care unit. J Intensive Care Med 1987; 02: 103-15.
89 Tovi D. The use of antifibrinolytic drugs to revent early recurrent aneurysmal haemorrhage. Acta Neurol Scand 1973; 49: 163-75.
90 Tovi D, Nilsson IM, Thulin CA. Fibrinolysis and subarachnoid haemorrhage. Inhibitory effect of tranexamic acid. A clinical study. Acta Neurol Scand 1972; 48: 393-402.
91 Tovi D, Nilsson IM, Thulin CA. Fibrinolytic activity of the cerebrospinal fluid after subarachnoid haemorrhage. Acta Neurol Scand 1973; 49: 1-9.
92 Tsementzis SE, Gill JS, Hitchcock ER. et al. Reduced platelet function in subarachnoid hemorrhage. J Neurosurg 1986; 64: 907-10.
93 Van Rossum J, Wintzen AR, Endtz LJ. et al. Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a doubleblind controlled clinical trial. Ann Neurol 1977; 02: 242-5.
94 Vassilouthis J, Richardson AE. Ventricular dilatation and communicating hydrocephalus following spontaneous subarachnoid hemorrhage. J Neurosurg 1979; 51: 341-51.
95 Vermeulen M. Antifibrinolytic treatment in aneurysmal subarachnoid hemorrhage. Proefschrift, Erasmus Universiteit Rotterdam. 1984
96 Vermeulen M, Lindsay KW, Murray GD. et al. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 1984; 311: 432-7.
97 Vermeulen M, van Vliet HH, Lindsay KW. et al. Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage. J Neurosurg 1985; 63: 573-7.